![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BD, Apax to Form $500 M Joint Venture for Respiratory Solutions
BD, Apax to Form $500 M Joint Venture for Respiratory Solutions
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
March 9, 2016
Becton, Dickinson and Company has entered an agreement to sell 50.1 percent of its Respiratory Solutions business to Apax Partners to form a joint venture.
The joint venture, which will operate as an independent company, will consist of Respiratory Solutions in its entirety, including Ventilation, Respiratory Diagnostics, Vital Signs and Airlife.
BD will maintain a non-controlling minority stake in the JV. The transaction falls just under $500 million and is expected to be completed by late fiscal year 2016 or early fiscal year 2017.
BD expects a share reduction of $0.10 to $0.14. — Anisa Jibrell
Upcoming Events
-
21Oct